NEW YORK, June 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=154641&from=4 CLASS PERIOD: March 7, 2024 to March 3, 202 ...

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024 and March 3, 2025. PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The Company’s lead product candidate was PGN-EDO51, a proprietary enhanced deliv ...

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submissio ...

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased PepGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE ...

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness and safety of its drug PGN-EDO51, leading to significant stock price declines and investor losses [2][4]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against PepGen [2]. - The complaint alleges that PepGen and its executives made false and misleading statements regarding the effectiveness and safety of PGN-EDO51 and the CONNECT2 study, which was deemed deficient for FDA approval [4]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a stock price drop of $5.55 per share, or 32.69%, closing at $11.43 [5][6]. - Following a clinical hold notice from the FDA on December 16, 2024, regarding the CONNECT2 study, PepGen's stock fell by $0.17 per share, or 3.63%, to close at $4.51 [7][8]. - On January 29, 2025, PepGen disclosed safety concerns in the CONNECT1 study, resulting in a stock price decline of $0.40 per share, or 21.74%, closing at $1.44 [9][10]. - The company announced a voluntary pause of the CONNECT2 study on March 4, 2025, leading to a further stock drop of $0.53 per share, or 18.86%, closing at $2.28 [10]. - On May 28, 2025, PepGen disclosed that PGN-EDO51 did not achieve target dystrophin levels and decided to discontinue its DMD programs [11].

Core Viewpoint - PepGen Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and efficacy of its lead product candidate, PGN-EDO51, and the adequacy of its clinical trials [3][4][5]. Company Overview - PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with PGN-EDO51 targeting Duchenne muscular dystrophy (DMD) [3]. Allegations and Events - The class action lawsuit claims that PepGen made false statements about PGN-EDO51's safety and effectiveness, inadequately conducted the CONNECT2 clinical trial, and overstated the product's clinical and regulatory prospects [3]. - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but the results were deemed disappointing by analysts, leading to a nearly 33% decline in stock price [4]. - On December 16, 2024, PepGen received a clinical hold notice from the FDA regarding the CONNECT2 study, causing further stock decline [5]. - On January 29, 2025, dosing in the CONNECT1 study was paused due to safety concerns, resulting in an approximate 22% drop in stock price [6]. - On March 4, 2025, PepGen announced a voluntary temporary pause of the CONNECT2 study, leading to another nearly 19% decline in stock price [7].

NEW YORK, June 26, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=154289&from=4CLASS PERIOD: March 7, 2024 to March 3, 2025 ...

Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was less effective and safe than previously stated by the defendants [2]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [2]. - The complaint asserts that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, making the defendants' public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until August 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen's management made materially false and misleading statements about PGN-EDO51's effectiveness and safety [3]. - It is claimed that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [3]. - The allegations suggest that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, resulting in misleading public statements by the defendants [3]. Group 2: Class Action Details - Shareholders who purchased shares of PepGen during the specified class period are encouraged to register for the class action, with a deadline of August 8, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].